Overview

A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function

Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to estimate the effect of moderate or mild hepatic impairment on the pharmacokinetic (PK) profile of a single oral dose of 40 mg vorasidenib in participants with hepatic impairment relative to healthy matched control participants with normal hepatic function.
Phase:
Phase 1
Details
Lead Sponsor:
Institut de Recherches Internationales Servier